Scientists test drug to prevent blood clots in COVID-19 patients

June 16, 2020  09:41

Scientists plan to test the experimental drug TRV027, developed by Trevena biopharmaceutical company, to prevent blood clots in COVID-19 patients. It is believed that the drug can balance hormones that affect blood pressure and blood vessels.

According to, approximately a third of patients hospitalized with COVID-19 form numerous blood clots, including in the lungs. The British Heart Foundation believes that this process may be caused by an imbalance between the hormones angiotensin II and angiotensin 1-7, which affect blood pressure and blood vessels. In a healthy person, this balance is maintained by the ACE-2 enzyme, which is located on the surface of cells and through which the SARS-CoV-2 virus enters the body.

The Foundation is organizing a study in which the experimental drug TRV027 will be tested in the treatment of patients with COVID-19 at the initial stage. According to preliminary data, it can restore hormonal imbalance and prevent blood clots. In the past, TRV027 was tested in the treatment of patients with heart failure: its effectiveness has not been proven, but it has proven to be safe.

The study is scheduled to begin next month, and 60 patients with suspected COVID-19 or with a confirmed diagnosis will take part in it. Within eight days, half of them will receive TRV027, the other half will receive a placebo along with standard treatment.

Eight days is a critical period for a COVID-19 patient, during which symptoms may worsen and treatment may be required in the intensive care unit. All this time, researchers will monitor the condition of volunteers.

Follow Medicine on Facebook and Twitter

  • Video
  • Event calendar
  • Archive